Bio-Techne Expands Oxford Nanopore Partnership Through 2032 for Advanced Genetic Diagnostics
核心洞察
Bio-Techne Corporation (搜索) has extended its collaboration with Oxford Nanopore Technologies (搜索) through 2032, expanding development of targeted genetic testing kits for heritable disorder screening and diagnosis.
The partnership builds on the successful 2025 launch of the AmplideX Nanopore Carrier Plus Kit (搜索), demonstrating Bio-Techne's strategic push into advanced genetic diagnostics.
The company also unveiled enhanced spatial biology technologies including RNAscope™ ISH technology (搜索) and Lunaphore COMET™ (搜索) solutions for simultaneous RNA and protein biomarker detection.
Bio-Techne Corporation (搜索) has significantly expanded its collaboration agreement with Oxford Nanopore Technologies (搜索), extending the partnership through 2032 and broadening its capabilities to develop and commercialize a wider range of targeted genetic testing kits for heritable disorder screening and diagnosis. This strategic move builds on the successful 2025 launch of the AmplideX Nanopore Carrier Plus Kit (搜索), underscoring Bio-Techne's commitment to advancing genetic diagnostics.
Strategic Partnership Expansion
The extended Oxford Nanopore partnership represents a key component of Bio-Techne's push deeper into the fast-growing field of advanced genetic diagnostics. The collaboration enables the company to leverage Oxford Nanopore's sequencing technology platform to develop more comprehensive genetic testing solutions for clinical applications.
The partnership expansion comes alongside Bio-Techne's July 2025 collaboration with Spear Bio (搜索) on ultrasensitive immunoassays, reinforcing the company's strategy to build scale in higher-growth, higher-margin diagnostic markets. These moves collectively support Bio-Techne's transition toward precision medicine applications.
Spatial Biology Technology Advancements
In addition to the Oxford Nanopore partnership, Bio-Techne recently announced new advancements in its spatial biology portfolio. The company unveiled enhanced RNAscope™ ISH technology (搜索) and Lunaphore COMET™ (搜索) solutions that enable simultaneous RNA and protein biomarker detection on the same tissue section.
These product developments are designed to help pathologists and researchers integrate spatial biology tools into existing diagnostic workflows, particularly in scenarios where tissue samples are limited or complex. The innovations in spatial multiomic analysis represent another avenue for Bio-Techne to strengthen its market position in advanced diagnostics.
Market Challenges and Growth Outlook
Despite these technological advances, Bio-Techne faces ongoing challenges from weak biotech and academic funding, which continues to pressure top-line growth and margins. The company's exposure to reduced R&D budgets amid global funding uncertainty remains a significant risk factor for near-term performance.
Bio-Techne has also established a partnership with the U.S. Pharmacopeia (搜索) to distribute reference materials, highlighting efforts to strengthen its market presence among biopharma clients as a key growth catalyst while external funding pressures persist.
Financial Projections
Bio-Techne's outlook anticipates $1.5 billion in revenue and $250.1 million in earnings by 2028. Achieving these targets would require 6.5% annual revenue growth and a $176.7 million increase in earnings from the current $73.4 million. The company's strategic focus on precision diagnostics and advanced genetic tools positions it to leverage long-term demand trends, though immediate recovery in core consumables demand may be limited by continued pressure on small biotech spending.